Business UpdateJun 2, 2026, 07:01 AM
Opus Genetics to Host R&D Science Forum on Gene Therapy Pipeline
AI Summary
Opus Genetics, a clinical-stage biopharmaceutical company, announced it will host a virtual Research & Development (R&D) Science Forum on June 16, 2026. The forum will showcase the company's multi-asset gene therapy pipeline for inherited retinal diseases, featuring management and key opinion leaders. It will provide detailed information on three gene therapy programs targeting RDH12, MERTK, and RHO mutations that are entering clinical testing, alongside updates on existing LCA5 and BEST1 clinical programs.
Key Highlights
- Opus Genetics to host virtual R&D Science Forum on June 16, 2026.
- Forum will highlight the company's multi-asset gene therapy pipeline.
- Detailed information on three gene therapy programs entering clinical testing.
- Programs target RDH12, MERTK, and RHO mutations for inherited retinal diseases.
- Summary of recently presented data from ongoing LCA5 and BEST1 clinical programs.
- Overview of IRD global market opportunities and patient prevalence.
- Event features management and key opinion leaders as guest speakers.
Price Impact
More from IRD